TICKERNERD
Menu
SLSSLSHealthcare · Biotechnology

SLS Stock Forecast: SELLAS Life Sciences Group, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$15
+15.41% on the day

The 2 Wall Street analysts covering SELLAS Life Sciences Group, Inc. hold a median 12-month price target of $33 — +110.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 65 of 100 as at 22 Aug 2026 — in the upper half.

Market cap
$3.1B
Ticker Nerd rank
65 / 100
Median analyst target
$33
Analysts covering
2
Total return, dividends reinvested
1W
+21.0%
1M
+19.9%
YTD
+310.2%
1Y
+778.7%
From 52W high
0.0%
From 52W low
+1012.6%
$1
$15
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

SLS stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores SELLAS Life Sciences Group, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
65 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
100
Value
92
Quality
78
Volatility
71
Revisions
63
Growth
33
Size
30
Accruals
29
Issuance
27

Momentum (100): The shares have been drifting up relative to others.

Issuance (27): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

SLS stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on SLS, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$10$20$30$40Oct 25Jan 26Apr 26Jul 26SLSHigh $35Median $33Low $30

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says2 analysts
2 Buy0 Hold0 Sell
Low $30Median $33High $35

The green dot is the last close — the median target sits +110.2% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
12 Mar 2026Maxim GroupMaintainsBuy$7.00 → $10
12 Mar 2026Maxim GroupMaintainsBuy—
16 July 2025Maxim GroupMaintainsBuy—
22 Nov 2023Cantor FitzgeraldReiteratesOverweight—
7 Sept 2023Cantor FitzgeraldReiteratesOverweight—
15 Nov 2022Alliance Global PartnersMaintainsBuy—
28 June 2022Cantor FitzgeraldMaintainsOverweight—
21 July 2021Cantor FitzgeraldInitiatesOverweight—
18 Nov 2019Alliance Global PartnersInitiatesBuy—
18 Nov 2019H.C. WainwrightInitiatesBuy—
18 Nov 2019Maxim GroupUpgradeBuy—
18 Nov 2019OppenheimerInitiatesOutperform—
15 Nov 2019Maxim GroupUpgradeBuy—
8 Apr 2019Alliance Global PartnersInitiatesBuy—
1 Nov 2018OppenheimerInitiatesOutperform—
20 July 2018Maxim GroupMaintainsBuy—
2 Apr 2018H.C. WainwrightInitiatesBuy—
2 Apr 2018HC Wainwright & Co.InitiatesBuy—
19 Mar 2018Maxim GroupUpgradeBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. SLS appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

SLS analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
2
Analysts cutting
0
Fundamentals

SELLAS Life Sciences Group, Inc. (SLS) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−61.9×

Cheaper than 99% of US stocks

Price / sales
—
Price / book
26.1×

Cheaper than 4% of US stocks

EV / EBITDA
−105.6×

Cheaper than 96% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−39.6%

Higher than 24% of US stocks

Return on assets
−23.3%

Higher than 17% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

SLS vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
SLSSELLAS Life Sciences Group, Inc.$3.1B
65
ARQTArcutis Biotherapeutics, Inc.$3.1B
88
CLDXCelldex Therapeutics, Inc.$3.1B
31
IMNMImmunome, Inc.$3.1B
33
TARSTarsus Pharmaceuticals, Inc.$3.1B
84
MBXMBX Biosciences, Inc.$3.2B
35
ALMSAlumis, Inc.$3.1B
51

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own SELLAS Life Sciences Group, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest SLS news & analysis

This One Data Readout Could Make Or Break Sellas Life Sciences Group

Seeking Alpha · 13 Aug 2026positive

The article discusses the pivotal Phase 3 REGAL trial readout for SELLAS Life Sciences Group's GPS in acute myeloid leukemia, noting the unusually long trial timeline and the company's $138.3 million cash position with funding targeted into 2027.

Why it matters — SLS watchers would care because the Phase 3 REGAL readout for GPS in AML is a key catalyst that could materially affect the company's outlook, while its cash position is described as supporting operations into 2027.

SELLAS Life Sciences Reports Second Quarter 2026 Financial Results and Provides Corporate Update

GlobeNewsWire · 11 Aug 2026positive

SELLAS Life Sciences Group reported its financial results for the second quarter ended June 30, 2026, and provided a corporate update. Key developments include the planned final analysis of the Phase 3 REGAL trial of Galinpepimut-S in acute myeloid leukemia following the 80th event, 28 patients enrolled in the Phase 2 trial of SLS009 in first-line AML with topline data expected in Q4 2026, and preclinical efficacy indications for SLS009 in advanced pancreatic cancer. The company reported $138.3 million in cash and cash equivalents as of June 30, 2026.

Why it matters — This update outlines the progress and timelines of SELLAS's two lead clinical programs and confirms the company's cash position, providing SLS watchers with key data points on upcoming trial readouts and financial runway.

Stock Picks From Seeking Alpha's July 2026 New Analysts

Seeking Alpha · 6 Aug 2026neutral

Seeking Alpha welcomed 33 new analysts in July 2026 and showcased their top picks and strategies. SELLAS Life Sciences is among the highlighted companies featured with detailed investment theses, alongside Chevron, B2Gold, Amazon, and QXO.

Why it matters — SELLAS Life Sciences was selected by new Seeking Alpha analysts as one of their top picks, drawing attention to the company from the investment community.

SELLAS Life Sciences: The Ownership Structure Has Changed Before The Defining Catalyst

Seeking Alpha · 2 Aug 2026positive

SELLAS Life Sciences approaches its pivotal REGAL readout with a transformed shareholder base, a stronger balance sheet, and a new supply structure. Institutional ownership doubled to 36.34%, with passive and index-linked funds now dominating the register, while multi-strategy and quant funds have exited.

Why it matters — A SLS watcher would care because the shift toward passive and index-linked institutional holders, with volatility-driven quant funds exiting, could materially shape trading behavior around the upcoming binary REGAL catalyst.

FAQ

Frequently asked questions about SLS stock

What is the SLS stock price forecast for 2026-2027?

The 2 Wall Street analysts covering SELLAS Life Sciences Group, Inc. have a median 12-month price target of $33, with estimates ranging from $30 to $35. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is SLS stock a buy right now?

Of the 2 analysts covering SELLAS Life Sciences Group, Inc., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks SELLAS Life Sciences Group, Inc. 65 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank SLS?

As at 22 Aug 2026, SELLAS Life Sciences Group, Inc. ranks 65 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (100 of 100).

Will SLS stock go up?

No one can know that. What the data says: the median 12-month target from 2 analysts implies +110.2% from the last close, and Ticker Nerd's factor model ranks SELLAS Life Sciences Group, Inc. 65 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the SLS stock forecast for 2030?

No analyst covering SELLAS Life Sciences Group, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SLS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $30 to $35 over the next 12 months.

How has SLS stock performed over the past year?

SELLAS Life Sciences Group, Inc. returned +778.7% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does SELLAS Life Sciences Group, Inc. do?

Sellas Life Sciences Group Inc. is a late-stage clinical biopharmaceutical company specializing in novel therapies for a broad range of cancer indications.

What is the latest news on SLS?

The most recent item we track (Seeking Alpha, 13 Aug 2026): "This One Data Readout Could Make Or Break Sellas Life Sciences Group". The article discusses the pivotal Phase 3 REGAL trial readout for SELLAS Life Sciences Group's GPS in acute myeloid leukemia, noting the unusually long trial timeline and the company's $138.3 million cash position with funding targeted into 2027.

Company

About SELLAS Life Sciences Group, Inc.

Sellas Life Sciences Group Inc. is a late-stage clinical biopharmaceutical company specializing in novel therapies for a broad range of cancer indications. The company focuses on immunotherapies and targeted small-molecule drugs designed to address both hematologic malignancies and solid tumors. Its lead product candidate, galinpepimut-S (GPS), is a WT1-targeting peptide cancer immunotherapeutic intended for use across multiple tumor types characterized by overexpression of the Wilms Tumor 1 protein. Sellas Life Sciences Group Inc. is also developing SLS009 (tambiciclib), a highly selective cyclin-dependent kinase 9 (CDK9) inhibitor aimed at genetically defined, difficult-to-treat cancers. The company advances these assets through clinical trials and collaborations with partners such as Memorial Sloan Kettering Cancer Center, Merck & Co., and GenFleet Therapeutics, focusing on combination regimens and biomarker-driven development. Headquartered in New York City and founded in 2012, Sellas Life Sciences Group Inc. plays a specialized role in oncology by targeting relapse prevention, treatment-resistant disease, and maintenance settings within the healthcare sector.

CEO Dr. Angelos M. Stergiou M.D., ScD h.c. · 13 employees · United States · https://sellaslifesciences.com